This is the authors' abstract. We don't add key points for this paper.
The unicellular Tetrahymena enzymatically split the synthetic phosphodiester, 4-methylumbelliferyl phosphocholine substrate. The enzyme activity was completely blocked in vitro and drastically inhibited in vivo by G-protein activating fluorides (NaF; AIF4- and BeF3-). The phospholipase A2 inhibitor, quinacrine, and the protein phosphatase inhibitor, neomycin, inhibited the enzyme activity in vitro and activated it in vivo. Another phospholipase A2 inhibitor 4-bromo phenacyl bromide was ineffective in vivo and in vitro alike, as well as the cyclooxygenase inhibitor indomethacin. Results of these experiments indicate that some treatments could be specific for a well defined activity (e.g., phospholipase A2, G-protein) but subject to influence by other enzymes (e.g., phospholipase C, sphingomyelinase). The experiments call attention to the differences in the results of the in vivo and in vitro studies.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kovács et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: